We are live on ! Find out more
PHIO icon

Phio Pharmaceuticals
PHIO

5 hedge funds and large institutions have $230K invested in Phio Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

25% more funds holding

Funds holding: 4 → 5 (+1)

2.25% less ownership

Funds ownership: 4.04% → 1.79% (-2.3%)

13% less capital inflows, than outflows

Capital inflows: $111K | Capital outflows: $128K

Holders
5
Holders Change
+1
Holders Change %
+25%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$37K
2
Panagora Asset Management
Panagora Asset Management
Massachusetts
+$37K
3
UBS Group
UBS Group
Switzerland
+$37K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$74K
2
Bank of New York Mellon
Bank of New York Mellon
New York
-$37K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$14K
4
Wells Fargo
Wells Fargo
California
-$3K

PHIO Hedge Fund Activity: Q2 2017 in Review

5 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q2 2017, worth a combined $230K — down 19% from $284K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new PHIO positions and 2 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $37K. The largest seller was Vanguard Group, exiting entirely with an estimated $74K sold.

  • 5 institutional investors held Phio Pharmaceuticals (PHIO) as of Q2 2017, up from 4 in Q1 2017.
  • Funds reported $230K of Phio Pharmaceuticals stock for Q2 2017, down 19% quarter-over-quarter.
  • 3 funds opened new Phio Pharmaceuticals positions in Q2 2017 and 2 closed out, a net change of +1 holder.
  • The largest Phio Pharmaceuticals buyer in Q2 2017 was Citadel Advisors, an estimated $37K added.
  • The largest Phio Pharmaceuticals seller in Q2 2017 was Vanguard Group, an estimated $74K sold.

Based on aggregated 13F filings for Q2 2017.